Skip to main content
Top
Published in: Journal of Infection and Chemotherapy 3/2013

01-06-2013 | Original Article

Mumps Hoshino and Torii vaccine strains were distinguished from circulating wild strains

Authors: Akihito Sawada, Yoshiaki Yamaji, Tetsuo Nakayama

Published in: Journal of Infection and Chemotherapy | Issue 3/2013

Login to get access

Abstract

Aseptic meningitis and acute parotitis have been observed after mumps vaccination. Mumps outbreaks have been reported in Japan because of low vaccine coverage, and molecular differentiation is required to determine whether these cases are vaccine associated. RT-nested PCR was performed in the small hydrophobic gene region, and viruses were differentiated by restriction fragment length polymorphism assay. A total of 584 nucleotides were amplified. The PCR product of the Hoshino strain was cut into two fragments (313 and 271 nucleotides) by MfeI; that of the Torii strain was digested with EcoT22I, resulting in 332- and 252-nucleotide fragments. Both strains were genotype B and had an XbaI site, resulting in two fragments: 299 and 285 nucleotides. Current circulating wild types were cut only by XbaI or MfeI. However, the MfeI site of the wild types was different from that of the Hoshino strain, resulting in 451- and 133-nucleotide fragments. Using three restriction enzymes, two mumps vaccine strains were distinguished from wild types, and this separation was applied to the identification of vaccine-related adverse events.
Literature
1.
go back to reference Kimura M, Kuno-Sakai H, Yamazaki S. Adverse events associated with MMR vaccines in Japan. Acta Paediatr Jpn. 1996;38:205–11.PubMedCrossRef Kimura M, Kuno-Sakai H, Yamazaki S. Adverse events associated with MMR vaccines in Japan. Acta Paediatr Jpn. 1996;38:205–11.PubMedCrossRef
2.
go back to reference Ueda K, Miyazaki C, Hidaka Y, Okada K, Kusuhara K, Kadoya R. Aseptic meningitis caused by measles–mumps–rubella vaccine in Japan. Lancet. 1995;346:701–2.PubMedCrossRef Ueda K, Miyazaki C, Hidaka Y, Okada K, Kusuhara K, Kadoya R. Aseptic meningitis caused by measles–mumps–rubella vaccine in Japan. Lancet. 1995;346:701–2.PubMedCrossRef
3.
go back to reference Nagai T, Okafuji T, Miyazaki C, Ito Y, Kamada M, Kumagai T, et al. A comparative study of the incidence of aseptic meningitis in symptomatic natural mumps patients and monovalent mumps vaccine recipients in Japan. Vaccine. 2007;25:2742–7.PubMedCrossRef Nagai T, Okafuji T, Miyazaki C, Ito Y, Kamada M, Kumagai T, et al. A comparative study of the incidence of aseptic meningitis in symptomatic natural mumps patients and monovalent mumps vaccine recipients in Japan. Vaccine. 2007;25:2742–7.PubMedCrossRef
4.
go back to reference Jin L, Rima B, Brown D, Örvell C, Técle T, Afzal M, et al. Proposal for genetic characterization of wild-type mumps strains: preliminary standardisation of the nomenclature. Arch Virol. 2005;150:1903–9.PubMedCrossRef Jin L, Rima B, Brown D, Örvell C, Técle T, Afzal M, et al. Proposal for genetic characterization of wild-type mumps strains: preliminary standardisation of the nomenclature. Arch Virol. 2005;150:1903–9.PubMedCrossRef
5.
go back to reference WHO. Mumps virus nomenclature update: 2012. A report based on the WHO mumps nomenclature update meeting, Geneva, 22 September 2011. Wkly Epidemiol Rec. 2012;87:217–24. WHO. Mumps virus nomenclature update: 2012. A report based on the WHO mumps nomenclature update meeting, Geneva, 22 September 2011. Wkly Epidemiol Rec. 2012;87:217–24.
6.
go back to reference Sasaki K, Higashihara M, Inoue K, Igarashi Y. Studies on the development of a live attenuated mumps virus vaccine. Kitasato Arch Exp Med. 1976;49:43–52.PubMed Sasaki K, Higashihara M, Inoue K, Igarashi Y. Studies on the development of a live attenuated mumps virus vaccine. Kitasato Arch Exp Med. 1976;49:43–52.PubMed
7.
go back to reference Hoshino M, Nishimitsu M, Ichimori Y, Oka Y, Kouno R, Yamashita K, et al. Development of live attenuated mumps Torii vaccine strain: development and biological characteristics. Clin Virol. 1981;9:323–30. (in Japanese). Hoshino M, Nishimitsu M, Ichimori Y, Oka Y, Kouno R, Yamashita K, et al. Development of live attenuated mumps Torii vaccine strain: development and biological characteristics. Clin Virol. 1981;9:323–30. (in Japanese).
8.
go back to reference Kashiwagi Y, Takami T, Mori T, Nakayama T. Sequence analysis of F, SH, and HN genes among mumps virus strains in Japan. Arch Virol. 1999;144:593–9.PubMedCrossRef Kashiwagi Y, Takami T, Mori T, Nakayama T. Sequence analysis of F, SH, and HN genes among mumps virus strains in Japan. Arch Virol. 1999;144:593–9.PubMedCrossRef
9.
go back to reference Takahashi M, Nakayama T, Kashiwagi Y, Takami T, Sonoda S, Yamanaka T, et al. Single genotype of measles virus is dominant whereas several genotypes of mumps virus are co-circulating. J Med Virol. 1996;62:278–85.CrossRef Takahashi M, Nakayama T, Kashiwagi Y, Takami T, Sonoda S, Yamanaka T, et al. Single genotype of measles virus is dominant whereas several genotypes of mumps virus are co-circulating. J Med Virol. 1996;62:278–85.CrossRef
10.
go back to reference Inou Y, Nakayama T, Yoshida N, Uejima H, Yuri K, Kamada M, et al. Molecular epidemiology of mumps virus in Japan and proposal of two new genotypes. J Med Virol. 2004;73:97–104.PubMedCrossRef Inou Y, Nakayama T, Yoshida N, Uejima H, Yuri K, Kamada M, et al. Molecular epidemiology of mumps virus in Japan and proposal of two new genotypes. J Med Virol. 2004;73:97–104.PubMedCrossRef
11.
go back to reference Otto W, Mankertz A, Santibanez S, Saygilli H, Wenzel J, Jilg E, et al. Ongoing outbreak of mumps affecting adolescents and young adults in Bavaria, Germany, August to October 2010. Eur Surveill 2010;15(50):19748 Otto W, Mankertz A, Santibanez S, Saygilli H, Wenzel J, Jilg E, et al. Ongoing outbreak of mumps affecting adolescents and young adults in Bavaria, Germany, August to October 2010. Eur Surveill 2010;15(50):19748
12.
go back to reference Kashiwagi Y, Kawashima H, Takekuma K, Hoshika A, Mori T, Nakayama T. Detection of mumps virus genome directly from clinical samples and a simple method for genetic differentiation of the Hoshino vaccine strain from wild strains of mumps virus. J Med Virol. 1997;52:195–9.PubMedCrossRef Kashiwagi Y, Kawashima H, Takekuma K, Hoshika A, Mori T, Nakayama T. Detection of mumps virus genome directly from clinical samples and a simple method for genetic differentiation of the Hoshino vaccine strain from wild strains of mumps virus. J Med Virol. 1997;52:195–9.PubMedCrossRef
13.
go back to reference Yoshida N, Fujino M, Ota Y, Notomi T, Nakayama T. Simple differentiation of mumps Hoshino vaccine strain from wild strains by reverse transcription loop-mediated isothermal amplification (RT-LAMP). Vaccine. 2007;25:1281–6.PubMedCrossRef Yoshida N, Fujino M, Ota Y, Notomi T, Nakayama T. Simple differentiation of mumps Hoshino vaccine strain from wild strains by reverse transcription loop-mediated isothermal amplification (RT-LAMP). Vaccine. 2007;25:1281–6.PubMedCrossRef
14.
go back to reference CDC. Mumps epidemic—United Kingdom, 2004–2005. MMWR. 2006;55:173–5. CDC. Mumps epidemic—United Kingdom, 2004–2005. MMWR. 2006;55:173–5.
15.
go back to reference CDC. Mumps outbreak at a summer camp: New York, 2005. MMWR. 2006;55:175–7. CDC. Mumps outbreak at a summer camp: New York, 2005. MMWR. 2006;55:175–7.
16.
go back to reference Barskey AE, Glasser J, LeBaron CW. Mumps resurgences in the United States: a historical perspective on unexpected elements. Vaccine. 2009;27:6186–95.PubMedCrossRef Barskey AE, Glasser J, LeBaron CW. Mumps resurgences in the United States: a historical perspective on unexpected elements. Vaccine. 2009;27:6186–95.PubMedCrossRef
17.
go back to reference Rubin SA, Audet SA, Sullivan B, Carbone KM, Bellini WJ, Rota PA, et al. Antibody induced by immunization with Jeryl Lynn mumps vaccine strain effectively neutralizes a heterologous wild-type mumps virus associated with a large outbreak. J Infect Dis. 2008;198:508–15.PubMedCrossRef Rubin SA, Audet SA, Sullivan B, Carbone KM, Bellini WJ, Rota PA, et al. Antibody induced by immunization with Jeryl Lynn mumps vaccine strain effectively neutralizes a heterologous wild-type mumps virus associated with a large outbreak. J Infect Dis. 2008;198:508–15.PubMedCrossRef
18.
go back to reference Rubin SA, Link MA, Sauder CJ, Zhang C, Ngo L, Rima BK, et al. Mumps outbreaks in vaccinated populations: no evidence of immune escape. J Virol. 2012;86:615–20.PubMedCrossRef Rubin SA, Link MA, Sauder CJ, Zhang C, Ngo L, Rima BK, et al. Mumps outbreaks in vaccinated populations: no evidence of immune escape. J Virol. 2012;86:615–20.PubMedCrossRef
19.
go back to reference Atrasheuskaya AV, Blatun EM, Kulak MV, Atrasheuskaya A, Karpov IA, Rubin S. Investigation of mumps vaccine failures in Minsk, Belarus, 2001–2003. Vaccine. 2007;25:4651–8.PubMedCrossRef Atrasheuskaya AV, Blatun EM, Kulak MV, Atrasheuskaya A, Karpov IA, Rubin S. Investigation of mumps vaccine failures in Minsk, Belarus, 2001–2003. Vaccine. 2007;25:4651–8.PubMedCrossRef
20.
go back to reference Takami T, Kawashima H, Takei Y, Miyajima T, Mori T, Nakayama T, et al. Usefulness of nested PCR and sequence analysis in a nosocomial outbreak of neonatal enterovirus infection. J Clin Virol. 1998;11:67–75.PubMedCrossRef Takami T, Kawashima H, Takei Y, Miyajima T, Mori T, Nakayama T, et al. Usefulness of nested PCR and sequence analysis in a nosocomial outbreak of neonatal enterovirus infection. J Clin Virol. 1998;11:67–75.PubMedCrossRef
21.
go back to reference Nakayama T, Onoda K. Vaccine adverse events reported in post-marketing study of the Kitasato Institute from 1994–2004. Vaccine. 2007;25:570–6.PubMedCrossRef Nakayama T, Onoda K. Vaccine adverse events reported in post-marketing study of the Kitasato Institute from 1994–2004. Vaccine. 2007;25:570–6.PubMedCrossRef
22.
go back to reference Plotkin SA, Rubin SA. Mumps vaccine. In: Plotkin SA, Orenstein W, Offit P, editors. Vaccines. 5th ed. Philadelphia: Saunders Elsevier; 2008. p. 435–65. Plotkin SA, Rubin SA. Mumps vaccine. In: Plotkin SA, Orenstein W, Offit P, editors. Vaccines. 5th ed. Philadelphia: Saunders Elsevier; 2008. p. 435–65.
23.
go back to reference Yung CF, Andrews N, Bukasa A, Brown KE, Ramsay M. Mumps complications and effects of mumps vaccination, England and Wales, 2002–2006. Emerg Infect Dis. 2011;17:661–7.PubMedCrossRef Yung CF, Andrews N, Bukasa A, Brown KE, Ramsay M. Mumps complications and effects of mumps vaccination, England and Wales, 2002–2006. Emerg Infect Dis. 2011;17:661–7.PubMedCrossRef
24.
go back to reference Hashimoto H, Fujioka M, Kinumaki H, Kinki Ambulatory Pediatrics Study Group. An office-based prospective study of deafness in mumps. Pediatr Infect Dis J. 2009;28:173–5.PubMedCrossRef Hashimoto H, Fujioka M, Kinumaki H, Kinki Ambulatory Pediatrics Study Group. An office-based prospective study of deafness in mumps. Pediatr Infect Dis J. 2009;28:173–5.PubMedCrossRef
Metadata
Title
Mumps Hoshino and Torii vaccine strains were distinguished from circulating wild strains
Authors
Akihito Sawada
Yoshiaki Yamaji
Tetsuo Nakayama
Publication date
01-06-2013
Publisher
Springer Japan
Published in
Journal of Infection and Chemotherapy / Issue 3/2013
Print ISSN: 1341-321X
Electronic ISSN: 1437-7780
DOI
https://doi.org/10.1007/s10156-012-0515-3

Other articles of this Issue 3/2013

Journal of Infection and Chemotherapy 3/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine